Volatility And Valuations Among Factors Weighing On Pharma Deal Making

Market volatility, persistently high valuations, inflation and interest rates are among the issues sidetracking broader M&A, experts say.

risk reward
Drug makers are trying to balance risk and reward when it comes to dealmaking • Source: Shutterstock

Macroeconomic issues and stock market volatility, coupled with high valuations for assets, have created uncertainty in the biopharmaceutical deal-making landscape despite interest across the sector to get deals done, according to experts speaking at the Financial Times US Pharma and Biotech Summit in New York on 11 May.

"All of our clients are looking at it, saying, ‘There are deals to be had if we can find the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business